Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Curbing C. difficile's toxin production

Curbing C. difficile's toxin production

September 06, 2007

As if being admitted to the hospital weren't bad enough, patients, once admitted, are at higher risk of becoming infected with a "superbug" bacterium, Clostridium difficile (C. difficile). The toxins produced by C. difficile kill human intestinal cells by causing them to burst open, allowing the bacteria to use them as fuel. This results in severe diarrhea and, in rare cases, death. Abraham "Linc" Sonenshein, PhD, and colleagues from the Department of Molecular Biology and Microbiology at the Tufts University School of Medicine (TUSM) and the Sackler School of Graduate Biomedical Sciences at Tufts, have discovered how a protein called CodY regulates the genes that control production of the dangerous toxins. Understanding the relationship between CodY and C. difficile is an important step toward the development of a drug that may prevent hospital patients from falling ill.

"The C. difficile bacteria only produce toxins when they are in need of food," explains Sonenshein, professor of microbiology at TUSM and corresponding author on the paper to be published in Molecular Microbiology. "We found that the CodY protein, in essence, monitors the hunger level of C. difficile, preventing toxin production when the bacteria have enough to eat." Sonenshein, along with first author Sean Dineen, PhD, and other Tufts colleagues developed a series of experiments to investigate the importance of CodY and how this protein communicates to bacteria that it is time to search for new sources of food.




The researchers first developed a mutant strain of C. difficile bacteria that does not make the protein CodY, and compared the amount of toxin produced by the mutant strain of bacteria to the amount of toxin produced by normal bacteria. The mutant strain produced much higher levels of toxin. The presence of CodY seems to tell the bacterial cells that they are well-fed and there is no reason to make toxin that kills intestinal cells for fuel. Lack of CodY activity, however, indicates to the bacteria that they are lacking key nutrients and that it is time to make the toxins they need to get food from the host cells.

To determine how CodY tells the bacteria not to make toxins, Sonenshein and colleagues removed DNA from the bacteria, and observed the interaction of the DNA and the CodY protein in vitro. They found that CodY targeted the region of the bacterial chromosome that includes the toxin genes. "When CodY senses that the cell has enough nutrients, it binds to this gene region, and prevents the bacterium from making toxin," says Sonenshein. "Conversely, when food is scarce, the CodY protein does not bind to these genes, allowing C. difficile to make the toxins needed to attack intestinal cells."

Knowing what turns on, and more importantly, what turns off the toxin-producing genes in C. difficile opens the door for treatment and prevention options. "It is possible that, based on our findings, a new drug could be developed that would trick CodY into thinking there is enough fuel for the bacteria, causing CodY to remain bound to the toxin gene region and thus suppressing toxin production."

Tufts University, Health Sciences



Related Clostridium Difficile Current Events and Clostridium Difficile News Articles Clostridium Difficile Current Events and Clostridium Difficile News RSS Clostridium Difficile Current Events and Clostridium Difficile News RSS
Is re-emerging superbug the next MRSA?
Loyola physicians warn little-known bacteria Clostridium difficile next emerging disease threat, killing 1,000s in the United State.

Advances in C. difficile research
New research into the toxins, virulence, spread and prevention of the superbug Clostridium difficile is reported in the June special issue of the Journal of Medical Microbiology. These findings will play a crucial role in providing us with ammunition in the fight against a sometimes deadly pathogen.

The balance shifts
The risk of contracting a Clostridium difficile infection following operations for which a "prophylactic" antibiotic is given to prevent infection is 21 times greater now than it was just a decade ago, according to researchers from the University of Sherbrooke in Canada. They report their findings in the June 15 issue of Clinical Infectious Diseases, currently available online.

ASGE issues updated infection control guidelines for gastrointestinal endoscopy
The American Society for Gastrointestinal Endoscopy (ASGE) has updated its infection control guidelines regarding gastrointestinal (GI) endoscopy.

UV lotion lights the way to cleaner facilities
A team of Canadian scientists using a lotion which glows under ultraviolet light have shown that up to a third of patient toilets are not properly cleaned.

Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrence
C. diff-associated disease (CDAD), otherwise known as severe intestinal disease brought on by the Clostridium difficile (C. diff) pathogen, has been the subject of heightened concern in the medical community.

MRSA in hospital intensive care -- what's growing where?
Researchers are finding out which bugs grow in intensive care units to develop a novel sampling regime that would indicate the threat of MRSA and other superbugs in the environment, scientists heard today (Monday 31 March 2008) at the Society for General Microbiology's 162nd meeting being held this week at the Edinburgh International Conference Centre.

APIC launches first national C. difficile prevalence study
The Association for Professionals in Infection Control and Epidemiology (APIC) today announced a detailed strategy to combat Clostridium difficile-associated disease (CDAD).

Confronting the challenge of antimicrobial resistance
Drug resistance is making many diseases increasingly difficult--and sometimes impossible--to treat, according to Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States.
More Clostridium Difficile Current Events and Clostridium Difficile News Articles


Clostridium difficile (Current Topics in Microbiology and Immunology)

Clostridium difficile has been recognized as the cause of a broad spectrum of enteric disease ranging from mild antibiotic-associated diarrhea to pseudomembranous colitis. This volume gives new insights into the microbiology, diagnostics and epidemiology of Clostridium difficile and describes recent strategies in treatment of diseases caused by this agent. Main parts of the volume are devoted to...



Bacteria for Breakfast: Probiotics for Good Health
by Kelly Dowhower Karpa, PhD, RPh

Although in Western society the beneficial aspects of bacteria have been increasingly minimized, we actually need bacteria in our digestive tracts for good health. This resource explains, to laymen and physicians, how probiotics support immune function, prevent urogenital infections, and maintain good gastrintestinal...

Recognizing and Managing Clostridium Difficile-Associated Diarrhea.: An article from: MedSurg Nursing
by Joanne M. Miller, Jane C. Walton, Lydia L. Tordecilla

This digital document is an article from MedSurg Nursing, published by Jannetti Publications, Inc. on December 1, 1998. The length of the article is 5268 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.From the...

Search goes on for effective therapies to combat CDAD.(Infectious Diseases)(Clostridium difficile associated diarrhea): An article from: Family Practice News
by Kerri Wachter

This digital document is an article from Family Practice News, published by Thomson Gale on September 15, 2006. The length of the article is 1012 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:...

Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003 (1).(RESEARCH) : An article from: Emerging Infectious Diseases
by L. Clifford McDonald, Maria Owings, Daniel B. Jernigan

This digital document is an article from Emerging Infectious Diseases, published by Thomson Gale on March 1, 2006. The length of the article is 5384 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:...

Clostridium Difficile: Its Role in Intestinal Disease
by Rial D. Rolfe

Toxic Clostridium difficile strain seen in nine states.(Infectious Diseases): An article from: Internal Medicine News
by Betsy Bates

This digital document is an article from Internal Medicine News, published by Thomson Gale on June 1, 2005. The length of the article is 860 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Toxic...

Clostridium difficile in retail ground meat, Canada.(DISPATCHES)(Clinical report): An article from: Emerging Infectious Diseases
by Alexander Rodriguez-Palacios, Henry R. Staempfli, Todd Duffield, J. Scott Weese

This digital document is an article from Emerging Infectious Diseases, published by Thomson Gale on March 1, 2007. The length of the article is 2416 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:...

Clostridium difficile PCR ribotypes in calves, Canada.(RESEARCH): An article from: Emerging Infectious Diseases
by Alexander Rodriguez-Palacios, Henry R. Stampfli, Todd Duffield, Andrew S. Peregrine, Lise A. Trotz-Williams, Luis G. Arroyo, Jon S. Brazier, J. Scott Weese

This digital document is an article from Emerging Infectious Diseases, published by Thomson Gale on November 1, 2006. The length of the article is 6278 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Clostridium difficile--associated diarrhea not easily diagnosed. (Tied to Fluoroquinolone Use).: An article from: Internal Medicine News
by Miriam E. Tucker

This digital document is an article from Internal Medicine News, published by International Medical News Group on January 15, 2003. The length of the article is 701 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

© 2008 BrightSurf.com